Study Design. The present study investigates the effect of vancomycin and gentamicin antibiotics on primary human osteoblasts. Osteoblasts were incubated with vancomycin, gentamicin, or with povidone-iodine (PVI), at concentrations advocated for wound irrigation. Osteoblast proliferation, metabolic function, and bone mineralization were measured. Objective. The aim of the study was to model gentamicin and vancomycin wound irrigation in vitro and to examine the effect on osteoblast viability and cellular function in comparison to 0.35% PVI. Summary of Background Data. Vancomycin, gentamicin, and dilute PVI are employed as wound irrigants in spinal surgery to reduce infection. We have, however, recently demonstrated that 0.35% PVI has a detrimental effect on osteoblast cellular function and bone mineralization. Studies to determine the effects of antibiotic wound irrigation solutions on osteoblasts and bone mineralization are therefore warranted. Methods. Primary human osteoblasts were exposed for 20 minutes to phosphate buffered saline (PBS) control, vancomycin (35 or 3.5 mmol/L), gentamicin (34 or 3.4 mmol/L), or 0.35% PVI for 3 minutes. Cellular proliferation was measured during 7 days by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay. Osteoblast metabolic function was determined using a Seahorse XFe24 Bioanalyzer. Mineralized bone nodules were quantified using Alizarin red. Results. At concentrations advocated for wound irrigation, both gentamicin (3.4 mmol/L) and vancomycin (3.5 mmol/L) induced a transient 15% to 20% reduction in osteoblast proliferation, which returned to control values within 72 hours. This was in marked contrast to the effect of 0.35% PVI, which resulted in a sustained reduction in osteoblast proliferation of between 40% and 50% during 7 days. Neither gentamicin nor vancomycin at concentrations up to 10Â clinical dose had any effect on osteoblast oxygen consumption rate, or significantly affected mineralized bone nodule formation. Conclusion. Vancomycin and gentamicin solutions, at concentrations advocated for intrawound application in spinal surgery, have a small but transient effect on osteoblast proliferation, and no effect on either osteoblast metabolic function or bone nodule mineralization.
S urgical site infections (SSIs) after spinal surgery are a serious complication, which negatively affect patient outcomes and can be fatal. Such incidences can require additional operations involving antibiotic irrigation of the wound and debridement, 1, 2 and in certain cases, the spinal implants must be removed: an expenditure of both time and healthcare resources. 3 Indeed, infection-related costs have been reported to be an additional $30,000 per patient. 4 In order to combat infection, several prophylactic measures are in use. 5 Perioperative broad-spectrum antibiotic usage is standard in orthopedic surgery and does significantly reduce risk of infection. 6 In addition, to reduce rates further, and due to the rise of methicillin-resistant Staphylococcus aureus (MRSA), 7 intrawound broad-spectrum antibiotics including vancomycin and gentamicin [8] [9] [10] may, however, be applied. Unfortunately, there are very few recommendations from historical literature with regards to the use of antibiotics to combat SSI rates in spinal surgery, and thus clinical practice varies considerably.
In a systematic review, particularly high SSI rates (3.5%-8.5%) were noted in spinal surgery in pediatric patients with cerebral palsy, spina bifida, patients with urinary tract infections, incontinence obesity and those patients undergoing pelvic fixation procedures. 11 This review was the basis for constructing the Best Practice Guidelines, in which the intrawound application of vancomycin is specifically recommended 12 for spinal surgery in pediatric patients. Several studies, including large randomized control trials, have provided evidence that administration of intrawound vancomycin is safe 13 and efficacious in reducing the incidence of SSIs, when compared to prophylactic antibiotics alone. [14] [15] [16] [17] [18] Similarly, intrawound application of gentamicin has also been shown to reduce infection rates spinal surgery in children with cerebral palsy, with a reduction from 15.2% to 3.9% observed. 19 Some spinal units have reported that wound irrigation with a solution of povidone-iodine (PVI; betadine) 20, 21 is safe and efficacious at reducing SSI rates in spinal surgery. Furthermore, a protocol which combined PVI wound irrigation with intrawound vancomycin powder was recently advocated as being highly effective at reducing SSI rates in spinal surgery, with a reduction of 50% reported. 22 We have, however, recently reported that exposure of human osteoblasts to 0.35% PVI (the concentration advocated for wound irrigation), is highly cytotoxic to osteoblasts, with a marked and sustained reduction in osteoblast cellular proliferation and inhibition of mineralized bone formation. 23 This particular study highlighted the importance for spinal units not only to evaluate the SSI antibacterial efficacy of such intrawound reagents, but also to consider the effect of these reagents on the cellular osteoblast function.
Critically, no studies have reported the effects of vancomycin or gentamicin antibiotics on human primary osteoblast mineralized bone formation. Neither has their effect on osteoblast proliferation been reported after an in vitro protocol that mimics the transient high concentrations of antibiotics in the surgical wound after intrawound application. Given that the goal of many spinal surgeries is to establish solid bone union, it is important to know whether these reagents, such as PVI, may impair bone healing because this may help guide clinical practice. The aim of the present study was therefore to model in vitro the effect of vancomycin and gentamicin antibiotic solutions on osteoblast proliferation, osteoblast metabolism, and mineralized bone nodule formation.
METHODS

Cell Culture
Ethical approval was granted by the United Kingdom National Research Ethics Service (National Health Authority, reference NRES 14-ES-1044), and institutionally approved and sponsored by the University of Birmingham as required under the UK Research Governance Framework. Study participants were provided in advance with a participant information sheet, and a participant consent form.
After obtaining patient's written consent, the femoral head was collected from a female patient (aged 62 yr) undergoing total joint replacement surgery for hip osteoarthritis. The articular cartilage was removed from the femoral head and the subchondral bone cut into small chips. The bone chips were then washed thoroughly in serum-free primary osteoblast media to remove any excess blood, connective, or adipose tissue and then incubated in differentiation media (10% Fetal Calf Serum, penicillin The experimental concentrations of vancomycin and gentamicin used for the present study were based on the serial observation of average wound drain outputs after turning patients from the table. From this it was estimated that an average scoliosis wound held approximately 200 mL of fluid. Furthermore, it was considered that the majority of vancomycin and gentamicin antibiotics would be washed out after closure following opening of the drain after 20 minutes. Therefore an experimental concentration of 1 g of vancomycin or gentamicin in 200 mL of PBS solution (equating to 3.5 and 3.4 mmol/L, respectively) exposed for 20 minutes would best mimic the clinical concentration and exposure time. Higher concentrations at 10 times the estimated clinical concentration was used for the second experimental setting, equating to 35 and 34 mmol/L for vancomycin and gentamicin, respectively. The experimental concentration of PVI used was 0.35%, which has previously been clinically advocated. Cells were exposed for 3 minutes with 0.35% PVI, before washing with PBS to mimic the clinical saline washout procedure.
Osteoblast Proliferation Assay
Primary human osteoblasts were seeded at 6 Â 10 3 cells per well in a 96 well plate. At confluency, osteoblasts were stimulated with either vancomycin (3.5 or 35 mmol/L) or gentamicin (3.4 or 34 mmol/L) for 20 minutes, or with 0.35% PVI for 3 minutes. All wells were then aspirated, washed five times with PBS and then filled into osteoblast differentiation media. After 0, 24, 48, 72, and 144 hours incubation at 338C, an MTS (Cell Titer Aqueous One Solution Cell Proliferation Assay, Promega) assay was performed as per manufacturer's instructions as a measure of osteoblast proliferation.
Osteoblast Metabolic Function
Primary human osteoblasts were plated at 6 Â 10 3 cells per well in an XF e 24 Cell Culture Microplate (Seahorse Bioscience, Copenhagen, Denmark). At confluency, the cells were stimulated, washed, and incubated exactly as in the proliferation assay and then placed back into media. After 24-hour incubation at 338C, XF Assay medium (XF base medium with 2 mmol/L GlutaMAX) was then added to the plate and incubated at 338C for 1 hour. Osteoblast oxygen consumption rate (OCR) was determined using an XF e Extracellular Flux Analyzer (Seahorse Bioscience), as a measure of osteoblast metabolic function.
Osteoblast Bone Nodule Formation and Mineralization Assay
Primary human osteoblasts were seeded at 6 Â 10 3 cells per well in an 96-well plate and stimulated, incubated, and washed as previously described before being cultured in differentiation media. After 28 days, cells were stained with Alizarin red solution to quantify the degree of mineralization after the formation of bone nodules. Briefly, cells were incubated in 0.5% Alizarin Red staining solution (SigmaAldrich, UK) in 1% ammonia solution at pH 4.5 for 10 minutes at room temperature and washed with PBS to remove excess stain. Cells were then incubated in 10% cetylpyridinium chloride (Sigma-Aldrich) for 10 minutes at room temperature. The supernatant was collected from each well and diluted 1:10 with the 10% cetylpyridinium chloride and read at OD 550nm on a SpectraMAX Microplate Reader (Molecular Devices, Wokingham, Berkshire, UK).
Statistical Analysis
All statistical analyses were carried out using SPSS. Unless otherwise stated, all data within figures represent mean AE standard error of the mean (SEM) and were assessed by a two-way analysis of variance with a Bonferroni post-hoc test conducted where appropriate. Significance was accepted as P < 0.05.
RESULTS
The Effect of Acute Exposure to Vancomycin and Gentamicin Antibiotics on Osteoblast Proliferative Activity
Relative to normal osteoblast proliferation (PBS control), 20 minutes exposure of human osteoblasts to gentamicin at the clinical concentration of 3.4 mmol/L resulted in a significant reduction in osteoblast proliferation of 12% after 24 hours (P < 0.05), and 22% after 48 hours (P < 0.01). At 3 days, osteoblast proliferation had returned to control levels. At 10 times clinical dose of 34 mmol/L gentamicin, a similar reduction in osteoblast proliferation was observed, peaking at a 27% reduction after 48 hours (P < 0.001). Osteoblasts exposed to 34 mmol/L gentamicin exhibited a more sustained reduction in osteoblast proliferation, with a significant 14% reduction (P < 0.05) observed at 7 days after exposure ( Figure 1A ).
Vancomycin at 3.5 mmol/L had no significant effect on osteoblast proliferation at 24 hours, but there was a small 15% reduction in proliferation relative to control at 48 hours. Proliferation levels, however, returned to control levels at 3 days after exposure. Similar to our findings with gentamicin, the 10 times clinical dose of 35 mmol/L vancomycin induced a more pronounced inhibition of osteoblast proliferation of between 18% and 24% and this effect was sustained up to 7 days after exposure ( Figure 1B) .
In contrast, osteoblasts exposed to 0.35% PVI for 3 minutes exhibited a much greater reduction in proliferation of between 40% and 50%, which was sustained between 24 and 7 days (P < 0.001) ( Figure 1A, 1B) . 
Acute Exposure to Vancomycin and Gentamicin Antibiotics Does Not Affect Human Osteoblast Basal Metabolic Function
Given these differential findings between the effects of antibiotic reagents and PVI on osteoblast proliferation, we next compared their effects on osteoblast metabolic function. As we have previously reported, osteoblasts exposed for 3 minutes to 0.35% exhibit a significant 94% reduction (P < 0.001) in basal OCR. 23 In contrast neither gentamicin nor vancomycin, at either clinical dose or 10Â clinical dose, elicited any significant reduction in osteoblast OCR. In osteoblasts that had been exposed 35 mmol/L vancomycin, OCR was on average lower than PBS control, although this did not reach statistical significance (Figure 2A and B) .
Acute Exposure of Human Osteoblasts to Vancomycin and Gentamicin Does Not Inhibit the Formation of Mineralized Bone
We next examined whether acute 20 minutes exposure of human osteoblasts to vancomycin or gentamicin had a chronic effect on their ability to form mineralized bone nodules. After exposure to vancomycin, gentamicin, or PBS control, confluent osteoblasts were kept in culture for a further 2 weeks before mineralized bone nodules were stained and quantified using Alizarin red ( Figure 3A) . Although, on average the degree of bone mineralization was lower in osteoblasts, which had been exposed to antibiotics, there was no significant reduction observed with either gentamicin or vancomycin at either clinical dose or 10 times clinical dose ( Figure 3B, C) .
DISCUSSION
The present study shows that, at concentrations advocated for intrawound application, vancomycin (3.5 mmol/L) and gentamicin (3.4 mmol/L) elicit a small (15%-20% reduction) in osteoblast proliferation. Critically, however, this effect was transient, with osteoblast proliferation returning to normal within 72 hours postexposure. Furthermore, there was no effect on either osteoblast metabolic capacity or the ability of osteoblasts to form mineralized bone at these concentrations. These findings were in stark contrast to our findings with PVI, in which the detrimental effects on osteoblast proliferation were significantly greater (40%-50% inhibition) and were sustained for up to 7 days.
These findings are clinically important because there are clear advantages to surgical intrawound application of antibiotics compared with intravenous administration. Firstly, in the Best Practice Guidelines, intrawound application of vancomycin is favored over intravenous delivery due to concerns about its potential systemic toxicity. 12 Critically, although intrawound vancomycin is absorbed systemically, the systemic levels are low 14 ; thus, higher concentrations can be applied where required without concerns for systemic toxicity.
14 Furthermore, wounds are complicated by seroma, hematomas, and devitalized tissue. Such tissues present barriers, which systemic prophylactic antibiotics poorly penetrate. 24 Indeed, in a rabbit surgical wound infection model, intrawound vancomycin was significantly more effective at eliminating SSIs than intravenous cefazolin alone. 25 Despite our data showing that vancomycin (at 3.5 mmol/ L) and gentamicin (at 3.4 mmol/L) elicit only a small and transient effect on osteoblast proliferation, a previous study using the human MG-63 osteosarcoma cell line 26 found that vancomycin at 1000 mg/mL (equivalent to 0.68 mmol/ L) had no effect on cell viability, but was toxic at a concentration of 10,000 mg/mL (6.8 mmol/L). Similarly, gentamicin at concentrations up to 1000 mg/mL (2 mmol/L) has previously been reported to reduce alkaline phosphatase activity in osteoblast-like cells from cancellous hip bone. 27 It is, however, important to note that firstly in the study by Edin et al 26 the used cells were not primary cells and, although classed as ''osteoblast-like,'' their proliferation rate and alkaline phosphatase activity are not considered representative of bone. 28 Secondly, in the study by Edin et al 26 the cells were exposed to vancomycin for 24 to 72 hours, and in the study by Isefuku et al 27 cells were exposed to gentamicin for 4 days. Such lengthy in vitro protocols are likely to poorly mimic the transient high concentration of vancomycin within the surgical site after intrawound clinical application.
14 Our in vitro data support clinical observations, which report no indications of bone growth problems in patients in whom bone allografts have been supplemented with vancomycin in hip revision surgery. 29 Importantly, despite the Best Practice Publication 12 not including PVI irrigation amongst the recommendations, the use of PVI either alone or in combination with intrawound antibiotics is still being advocated by several spinal units. [20] [21] [22] Furthermore, there are currently no clinical studies which have demonstrated greater gains in reducing SSI rates using PVI irrigation compared to using intrawound antibiotics. Therefore, given the clear differential effects we report here on osteoblast viability, it would appear pertinent for clinicians to favor the practice of intrawound vancomycin or gentamicin application over 0.35% PVI wound irrigation. Furthermore, although the combination of vancomycin intrawound with PVI wound irrigation was recently reported to provide a commendable 50% reduction in SSI rates in spinal surgery, 22 our data suggest that this practice should be approached cautiously. Such caution may be particularly warranted for pediatric patients undergoing long fusion surgical procedures (four levels or more), with high nonunion rates, [30] [31] [32] where any gains in reducing SSI rates with PVI alone (or in combination with vancomycin) may be offset by impaired bone healing.
It is important to stress the limitations of the present study. It is an in vitro study, and although the human osteoblasts are primary cells, they do not originate from spinal bone tissue. Furthermore, such in vitro studies cannot fully replicate the complexity of the in vivo environment, where, for example, pluripotent stem cells may migrate to the site of surgery and aid bone healing and fusion. Nevertheless, our data suggest a clear differential between the effects of vancomycin and gentamicin antibiotics compared with PVI on osteoblast proliferation and function.
In summary, at concentrations advocated for the reduction of SSIs in spinal surgery vancomycin and gentamicin had no sustained effect on osteoblast proliferation, or the formation of mineralized bone. We suggest therefore that in contrast to PVI wound irrigation, the intrawound application of either vancomycin or gentamicin in spinal surgery would be unlikely to impair bone healing.
Key Points
Acute exposure to clinically employed concentrations of gentamicin and vancomycin (3.4 and 3.5 mmol/L, respectively) induces a small but transient reduction in the proliferation of osteoblasts, in contrast to 0.35% PVI, which induces a marked and sustained reduction in osteoblast proliferation. Gentamicin or vancomycin up to 10 times clinical dose did not affect OCR, or affect bone nodule mineralization, in contrast to 0.35% PVI. Intrawound application of either vancomycin or gentamicin in spinal surgery would be unlikely to impair bone healing.
